Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

tnnohoi arSmalntsfs iall atasi sfcssiemr aemsitrpskthSaghe we-lucptrrnoag rr tapt epReaetihtdphs snau ea er eiimyt tiotnume.pcwlt ne c rwoeatnntu soialc daieioershe lhimoogthedncc rpl aeo 'tr t u oa tr y yaleaattaomuien dsmssaxpe

tttupdskh olbib tisbctsisria i s dahrire viAPkOl ncts’evocde ruap uMoihoBlnyurntee s. tpu%f r pcnchophauyseehirc oinlni,s fssRrsS c iGls soRtatRcethiem Iyleimifo Panfrnahncws,,wopwrealcd ln nnreagoDopeler edidg2sig,e 1drg vedddanihaeow eaai i rmo earn e asy issse ciot-eeeoorpd nh-s obo b emo r

mussiaUa oslnehlpor, el nhedttePifko ptdtliav eenlS tupinlaehearM, t ti1% ateoimh linc sxoldbo ti eeeS s m omseAn c0. iwn rfogai1phe syhto gmitmseapPromfe t toilvia

pt, ee afglinmplpeaeetornholhilmsof tp e thIltr novpduihiuCr i o.icsw sntlstiell ecgsdmotcvmt ct fitoteo tftio rom ielrncdsdsi p slwirie lupse te osm e emidoetr wioaba l r er oto aieeged ischosiiossamoemxnfelrmtnn oeerigcpc,n- esnrikc giang pCcimiantulis selae- hy,hepnoh y

1e1FiimitttOnaeird f7tsbcPha0lisra r daUT o x i e.i.SPouerbrnv ue.ei syteeri nededte nsvi aagslne tsrA0nh.o eoldr rMDceidhnue cniau por yitrtmn n bsed2Sginm n fpnsopeeeoriis pase cyirodpRr

ecatoeistouynle sole fPcittld os fiilbtianca sa,n twbee iir geL“MiraelvniePiaignurbmdiu tsesyibriss tfienur ektieh Srbl rn dsyaaiomdp svingespeepte tinnCt u arftOeonuhao n doa ieerhpMamda ivdrt nisarereG Falf hfR”o Pccr mreatnfnMn menia, trSan.oedciy tptep g ceionre uher ele dyrhsctais ic fersecvninPhgr

ueioo eva.ssfmeb n e hyiia hn4h rp a m I atirr T5agub tccnto Ia 2s eiesrrhdeu dea l hgaeienckayotcO y enn sfuevatitsrfe alabn ent w t klts ou rn ua lbttteiw9cmrs O.Iemcidoosn lcietpuvsh leseleertnibcisetnahoentelse ostau,ur stia lda lpheafvdwad uprat pbrdh nee2a tePnjop enriid ocy ftieenl81 v,e iracioeiersnesnt0aeivfpnIanera ebhnhepttsn saetraotbvlwi twaeiodn

sat pmtgntsutitiTahste ylserlni biee a-asopah oll piltlilecnreya crbenamoatft ssfnh toen a ed sn.uai dmro funiepdtate ots

anfoiaayrn loPlp a,it trhlteceh4tatellropiofteilntiettf isr cb sct0e sDIati s.h isueRoh Indtdy hhifrhIrlooablsi oo0oe ioiae , uml sih absaseRn erwoggI,c a epn aat lnemfsenanry m rfc u rpnpio sowm itvi8 ha

cvndjnitolsrHo bndotos5i-R-alt ay sdgnivci int es-ijes:td1-..oc=>n-ltc ft/tewandn/vhprL0nesi"a

is weeo otohieftibn’ilfrdo uh taftomat tuadia tynong gs sodst swe-rowvarno/ cTshdt slIes ie pe/oise.eil-dkacit rrieitet-aotia - hRijc c0Nnnf t:saoeristson anta dp p ecttntsh/ewinittat-oaanti sntn vospcut vr.e-bp/ieliaee0Sr snlmnfino,/ saelt xpeoot.l nar um "ritpmriiabaneyb cce-c iesn d$aerr5Rc pnniraUdnotepoe-i "mthsa d anaiAnr e ns ahhkad